BACKGROUND AND PURPOSE: Human Papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) respond favourably to radiotherapy as compared to HPV-unrelated HNSCC. We investigated DNA damage response in HPV-positive and HPV-negative HNSCC cell lines aiming to identify mechanisms, which illustrate reasons for the increased sensitivity of HPV-positive cancers of the oropharynx. METHODS: Radiation response including clonogenic survival, apoptosis, DNA double-strand break (DSB) repair, and cell cycle redistribution in four HPV-positive (UM-SCC-47, UM-SCC-104, 93-VU-147T, UPCI:SCC152) and four HPV-negative (UD-SCC-1, UM-SCC-6, UM-SCC-11b, UT-SCC-33) cell lines was evaluated. RESULTS: HPV-positive cells were more radiosensitive (mean SF2: 0.198 range: 0.22-0.18) than HPV-negative cells (mean SF2: 0.34, range: 0.45-0.27; p = 0.010). Irradiated HPV-positive cell lines progressed faster through S-phase showing a more distinct accumulation in G2/M. The abnormal cell cycle checkpoint activation was accompanied by a more pronounced increase of cell death after x-irradiation and a higher number of residual and unreleased DSBs. CONCLUSIONS: The enhanced responsiveness of HPV-related HNSCC to radiotherapy might be caused by a higher cellular radiosensitivity due to cell cycle dysregulation and impaired DNA DSB repair.
BACKGROUND AND PURPOSE:Human Papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) respond favourably to radiotherapy as compared to HPV-unrelated HNSCC. We investigated DNA damage response in HPV-positive and HPV-negative HNSCC cell lines aiming to identify mechanisms, which illustrate reasons for the increased sensitivity of HPV-positive cancers of the oropharynx. METHODS: Radiation response including clonogenic survival, apoptosis, DNA double-strand break (DSB) repair, and cell cycle redistribution in four HPV-positive (UM-SCC-47, UM-SCC-104, 93-VU-147T, UPCI:SCC152) and four HPV-negative (UD-SCC-1, UM-SCC-6, UM-SCC-11b, UT-SCC-33) cell lines was evaluated. RESULTS:HPV-positive cells were more radiosensitive (mean SF2: 0.198 range: 0.22-0.18) than HPV-negative cells (mean SF2: 0.34, range: 0.45-0.27; p = 0.010). Irradiated HPV-positive cell lines progressed faster through S-phase showing a more distinct accumulation in G2/M. The abnormal cell cycle checkpoint activation was accompanied by a more pronounced increase of cell death after x-irradiation and a higher number of residual and unreleased DSBs. CONCLUSIONS: The enhanced responsiveness of HPV-related HNSCC to radiotherapy might be caused by a higher cellular radiosensitivity due to cell cycle dysregulation and impaired DNA DSB repair.
Authors: Daisuke Sano; Tong-Xin Xie; Thomas J Ow; Mei Zhao; Curtis R Pickering; Ge Zhou; Vlad C Sandulache; David A Wheeler; Richard A Gibbs; Carlos Caulin; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-09-08 Impact factor: 12.531
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Jeroen J Mooren; Bernd Kremer; Sandra M H Claessen; Adri C Voogd; Fredrik J Bot; J Peter Klussmann; Christian U Huebbers; Anton H N Hopman; Frans C S Ramaekers; Ernst-Jan M Speel Journal: Int J Cancer Date: 2012-10-11 Impact factor: 7.396
Authors: D Dionysopoulos; K Pavlakis; V Kotoula; E Fountzilas; K Markou; I Karasmanis; N Angouridakis; A Nikolaou; K T Kalogeras; G Fountzilas Journal: Strahlenther Onkol Date: 2013-02-13 Impact factor: 3.621
Authors: Anjali K Gupta; John H Lee; Werner W Wilke; Harry Quon; Gareth Smith; Amit Maity; John M Buatti; Douglas R Spitz Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-01 Impact factor: 7.038
Authors: Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: Vanessa Vanderdys; Amir Allak; Fadila Guessous; Mouadh Benamar; Paul W Read; Mark J Jameson; Tarek Abbas Journal: Mol Cancer Ther Date: 2017-08-24 Impact factor: 6.261
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039